New England Journal of Medicine· 2018Q1
AR101 Oral Immunotherapy for Peanut Allergy
- 750citations
- Q1SCImago
- 2018year
Short summary
AR101 oral immunotherapy enabled 67.2% of children (4-17 yrs) to ingest >=600mg peanut protein vs. 4.0% on placebo, a 63.2 percentage point difference (P<0.001).
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Immunology and Allergy
Immunology and AllergyMedicine